The FDA's Drugs@FDA database lists a supplement dated 24 September to the new drug application for lenvatinib, the multi-kinase inhibitor used in thyroid, renal, hepatocellular and endometrial cancers. The record names the product and licence holder but does not state what the supplement covers.
Supplements can be labelling, manufacturing or new-indication changes; the database entry alone does not say which. Until the updated label is published, prescribing is unchanged.
The routine checks for lenvatinib stand: blood pressure control before and during treatment, proteinuria monitoring, thyroid function, and vigilance for haemorrhage and fistula.
- The 24 September entry is a licence supplement; the change is not specified.
- Control blood pressure before starting lenvatinib and monitor it closely.
- Check urine protein and thyroid function regularly on treatment.
- Review the updated FDA label before assuming any new indication or dosing.
Why it matters
Lenvatinib spans several tumour types, so a label change could touch several clinics at once.
Don't overread it
A licence supplement is not a new indication until the label says so.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free